i2 Innovation in Intervention Summit
William D. Knopf, MD, FACC*
Cardiac Services of St. Joseph’s Hospital of Atlanta, Atlanta Cardiology Group of Georgia, Atlanta, Georgia.
View larger version (18K):
[in a new window]
|
Figure 1 Nine-month clinical outcome for insulin-treated diabetic patients enrolled in the Strategic Transcatheter Evaluation of New Therapies (STENT) trial. Completed nine-month follow-up: 5,566, 93.7%. p = NS for all. Blue bars = sirolimus-eluting stent; yellow bars = paclitaxel-eluting stent. MACE = major adverse cardiac events; MI = myocardial infarction; TVR = target vessel revascularization.
|
|
View larger version (28K):
[in a new window]
|
Figure 2 Clinical Performance and Angiographic Results in Absorbable Metal Stents (PROGRESS-AMS) study: volumetric intravascular ultrasound parameters. No late incomplete opposition; no adverse edge effect. *p < 0.01. Blue bars = post-implantation; yellow bars = four-month follow-up. EEM = external elastic membrane.
|
|
View larger version (35K):
[in a new window]
|
Figure 3 Reduction in headache burden (frequency x duration) in the Migraine Intervention with StarFlex Technology (MIST) trial. p = 0.033. Blue bars = baseline; yellow bars = analysis.
|
|
|
